Apoptosis And Stem/Progenitor Cells In The Development And Treatment Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$21,809,604.00
Summary
To improve cancer therapy, we are studying two cancer hallmarks. The first is excessive cell survival. To combat this, we are developing drugs with commercial partners that directly activate the cell's death machinery. The second hallmark is inexorable proliferation, akin to that of stem cells, which can generate entire tissues, as we showed for the breast. ‘Rogue’ stem-like cells may initiate certain cancers. We hope to advance cancer therapy by identifying such cells and drugs that kill them.
Apoptosis And Stem Cells In Cancer Development And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$22,852,198.00
Summary
To improve cancer therapy, we are studying two cancer hallmarks: enhanced cell survival and stem cell-like behaviour. As we discovered, cell death is often blocked in cancer cells. Hence, we are attempting to develop drugs that flip the natural ‘cell death switch’. Stem cells are rare cells that generate entire tissues, as we showed for the breast. Certain cancers may be driven by ‘rogue’ stem cells. If so, eradication of these rare cells within the bulk tumour may require novel therapies.
Development And Evaluation Of An Internet-based Clinic For Stuttering.
Funder
National Health and Medical Research Council
Funding Amount
$6,200,965.00
Summary
Stuttering is a prevalent disorder of speech production. The program of research will establish the world’s first Internet-based stuttering clinic to service all the clinical needs of child, adolescent and adult patients. The Internet-based clinic model will provide economical, scalable and translatable stuttering treatments that will, for the first time, provide a means to adequately manage the public health problem of stuttering.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,006,551.00
Summary
Breast cancer is heterogeneous, making management a challenge. High-grade cancers including the ‘basal’ type are aggressive, often found in young women and have a propensity for distant spread. They are also associated with a BRCA1 gene mutation. We will study mechanisms that predispose some women to develop breast cancer, the process that allows cancers to grow at distant sites such as the brain and lungs, and how DNA repair proteins are implicated. This will allow development of new diagnostic ....Breast cancer is heterogeneous, making management a challenge. High-grade cancers including the ‘basal’ type are aggressive, often found in young women and have a propensity for distant spread. They are also associated with a BRCA1 gene mutation. We will study mechanisms that predispose some women to develop breast cancer, the process that allows cancers to grow at distant sites such as the brain and lungs, and how DNA repair proteins are implicated. This will allow development of new diagnostic tools and treatments.Read moreRead less
The Elimination Of Hepatitis C As A Global Public Health Threat
Funder
National Health and Medical Research Council
Funding Amount
$7,001,475.00
Summary
In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2 ....In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2030.Read moreRead less
Frontotemporal Dementia And Motor Neurodegenerative Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$17,069,580.00
Summary
Frontotemporal degeneration of the brain is a leading cause of morbidity due to a pathologically heterogeneous, rapidly-progressive group of disorders with behavioural, language and motor deficits. Our internationally recognized team will continue to develop the necessary tools and therapies to effectively diagnose, manage and treat these disorders. Our focus in this program is to understand the unusual genetics underpinning these disorders, and to fast track any potential treatments.
We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells. We wish to learn how cancer can sometimes evade the immune system. Our work will also find out how some common treatments for cancer, like chemotherapy, can be used to boost the immune system and eliminate tumours. Through knowledge gained from these studies, we aim to develop new therapies that can help patients with devastating diseases like cancer.